Adage Capital Partners’s Apellis Pharmaceuticals APLS Stock Holding History

Adage Capital Partners’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-31,000	Closed	-$1.6M	–	918
2022 Q4	$1.6M	Buy	+31,000	New	+$1.64M	﹤0.01%	823
2022 Q3	–	Sell	-460,000	Closed	-$20.8M	–	1049
2022 Q2	$20.8M	Buy	460,000 +135,000	+42%	+$6.16M	0.05%	409
2022 Q1	$16.5M	Buy	+325,000	New	+$14.3M	0.03%	551
2020 Q1	–	Sell	-100,000	Closed	-$3.06M	–	729
2019 Q4	$3.06M	Sell	100,000 -400,000	-80%	-$11.1M	0.01%	645
2019 Q3	$12M	Hold	500,000	–	–	0.03%	481
2019 Q2	$12.7M	Hold	500,000	–	–	0.03%	482
2019 Q1	$9.75M	Hold	500,000	–	–	0.02%	530
2018 Q4	$6.59M	Buy	500,000 +281,000	+128%	+$4.31M	0.02%	576
2018 Q3	$3.89M	Sell	219,000 -62,000	-22%	-$1.15M	0.01%	651
2018 Q2	$6.18M	Buy	+281,000	New	+$6.46M	0.01%	636

Other funds holding APLS

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners's APLS Position: Q1 2023 in Review

Adage Capital Partners sold out of Apellis Pharmaceuticals (APLS) in Q1 2023, closing a stake of 31,000 shares — an estimated $1.6M sold.

Adage Capital Partners first reported a position in APLS in Q2 2018 and held it in 10 quarters. The position peaked at $20.8M in Q2 2022. 281 funds tracked by Wall St. Rank hold APLS as of Q1 2023.

Adage Capital Partners reported no remaining Apellis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Adage Capital Partners sold 31,000 Apellis Pharmaceuticals shares in Q1 2023, an estimated $1.6M.
Adage Capital Partners first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 10 quarters.
Adage Capital Partners's Apellis Pharmaceuticals position peaked at $20.8M in Q2 2022.
281 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2023.

Based on Adage Capital Partners's 13F filing for Q1 2023, filed 15 May 2023.